November 2017 Vol 8, No 11
In this issue of the Journal of Oncology Navigation & Survivorship (JONS), we are proud to present the evidence-based research abstracts that have been accepted to the Eighth Annual Navigation & Survivorship Conference of the Academy of Oncology Nurse & Patient Navigators (AONN+).
Community Outreach: Inside a Community Tumor Board. Prevention, Treatment, and Survivorship in Breast Cancer
Heidi Eve-Cahoon, MSN, RN, CNP, CBCN, Sharon Lieb Inzetta, RN, MS, CBCN, CN-BN, Melanie Lynch, MD, FACS, Laura Musarra, BS, MBA
Today there are ever-increasing challenges surrounding breast cancer care. The ongoing disparities in delivering cancer care continue to impact our nation as a whole, and, more importantly, for both patients and providers in our local communities.
The tumor board, or multidisciplinary cancer conference (MCC), is the foundation of high-value multidisciplinary oncology care through coordinating teams of specialists.
Nora J. Barrett, BSN, RN, OCN, ONN-CG, Kristi C. Garrison, MS, CHES, CHW, OPN-CG, Stacey L. Webb, MPA-HCA, BSN, RN, ONN-CG
Currently, pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States. However, with the lack of early detection tests and treatment options, it is estimated that PC may move to the second leading cause of cancer death in the United States by 2020 or even earlier.
The Oncology Nurse Navigator’s Role in Enhancing the Multidisciplinary Cancer Conference at a Community Cancer Hospital
The multidisciplinary cancer conference (MCC) plays an integral role in optimizing patient outcomes in today’s increasingly complex world of cancer care.
Improving Compliance and Patient Outcomes with a Presurgery Gynecologic Oncology Educational Video and Survey
The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital, performs more than 500 surgeries annually.
Creating a Pediatric Cancer Immunotherapy Nurse Navigator Role: Developing Complex Care Coordination Processes
Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell ALL or have been refractory to standard therapy.
According to Morgan, “Lung Cancer is the leading cause of cancer-related death in the United States, claiming more lives than colon, breast, and prostate cancer combined.”
The Cancer Support Community (CSC) has designed a patient/provider discussion tool for patients with chronic myeloid leukemia (CML).
Each woman’s risk of developing breast cancer is different and depends on her lifestyle, family health history, and other factors. The American Cancer Society considers women who have a lifetime risk assessment of 20% or greater to be at high risk for breast cancer.
Carcinoid Syndrome Impact Survey: Evaluation of the Burden of Illness and the Gap Between Patient and Oncologist Perceptions
Patients with advanced neuroendocrine tumors may develop carcinoid syndrome, a rare condition characterized by debilitating symptoms, including diarrhea, flushing, and valvular heart damage, that can greatly affect patient social and physical functioning.
Structured Exercise Prescription Program: Targeting Monolingual Spanish-Speaking Patients to Improve Impairments
Keith Argenbright, MD, Emily Berry, MSPH, Stephanie Mamantov, ACSM/ACS, Tracy Mazour, RN, MSN, OCN, Aurelio Rodriguez, Lisa Ross, BS, ACSM/ACS
Exercise is a multipurpose tool that can be used to help cancer survivors improve their quality of life (QOL) across the cancer continuum.
JaLisa Boyd, MS, BSN, RN, Emily Gentry, BSN, RN, HON-ONN-CG, OCN, Katie Narvarte, LMSW, OSW-C, OPN-CG
Sarah Cannon Cancer Institute, the Oncology Service line for Medical City Healthcare in the Dallas/Fort Worth, Texas area, has a team of 13 disease-suite oncology nurse navigators and 2 survivorship navigators.
Efficacy of the Breast Cancer Navigator Role in Reducing Distress in Newly Diagnosed Breast Cancer Patients: A Pilot Study
The authors present their findings from a study testing the effects of an early intervention by the Breast Cancer Navigator on distress.
Examining the Mutual Benefits of a Peer Support Program to Facilitate Adaptation Among Women Affected by Breast/Ovarian Cancer: The Sharsheret Experience
Frank Riessman’s Helper Theory (1965) posits that peer support networks can be powerful tools to extend care delivery—benefiting both the giver and receiver of informal care.
Research has consistently found that caregivers for people with cancer report distress; however, it is not clear whether recent improvements in the treatment of chronic myelogenous leukemia (CML) have reduced caregiver burden.
Screening for Supportive Oncology Patient Concerns, Analyzing Impact and Opportunities to Improve Spiritual Questions Affecting Navigation to Spiritual Resources
The Institute of Medicine (IOM) 2013 report recommends that supportive oncology care start at cancer diagnosis; the Commission on Cancer (CoC) Standard 3.2 requires distress screening and indicated action.
The burden of cancer has largely focused on the patient. However, caregivers also experience considerable burden.
Carolyn Allsen, BSN, RN, OCN, ONN-CG, Sylvia Brown, MS, RN, OCN, CNL, ONN-CG, Sandra Miller, MHSM, RN, NE-BC
Since the inception of the oncology nurse navigator (ONN) program at Memorial Hermann Hospital System (MHHS) in 2009, the role of the ONN was vastly misunderstood, and the overall potential benefits for the hospital and patient were undefined.
Educational Needs Related to Nursing Skill Level and Awareness of Navigating the Complexities of the Cancer Care Continuum
The Academy of Oncology Nurse & Patient Navigators conducted a 1.5-day live conference April 27-29, 2017, in Phoenix, AZ.
Navigating the Course from Diagnosis to Survivorship: The Implementation of the Nurse Navigator Role in a Pediatric Oncology Cancer Center
Jackie Gonzalez, DNP, MBA, ARNP, NEA-BC, FANN, Lilliam Rimblas, RN, BSN, CPHON, Peggy Townsend, MSN, RN, CPON
Navigation is defined as the “guiding force promoting the timely movement of the patient through a complex system of care.”
Benefits of a Multidisciplinary Clinic Operations Workgroup as a Forum for Navigator Coordinators and Quality Improvement
Alyssa Pauls, RN, BSN, OCN, Kathleen Sevedge, RN, MA, AOCN, Cynthia Smith, RN, BSN, OCN, MA, Laura Beaupre, RN, BSN, OCN, CN-BN, Maritza Chicas, RN, BSN, OCN
Multidisciplinary care is recognized as a sign of quality cancer care according to several organizations, including the American Society of Clinical Oncology, the Institute of Medicine, the National Cancer Institute Community Cancer Centers Program (NCCCP), and the Oncology Roundtable.
The number of cancer survivors is increasing because of advances in detection and treatment.
Helping Breast Cancer Patients Manage Care Transitions Through Patient and Navigator Use of 4R Care Plans, 4R = Right Information/Care/Patient/Time
Transitions in care require well-managed timing and sequencing of events across specialties.
Impact of a Workplace Educational Webinar Series Focused on the Needs of Employees and Their Family Members Living with a Cancer Diagnosis
As people with a history of cancer are living longer and surviving their cancer, today it is estimated that there are 14 million cancer survivors in the United States.
Impact on Caregivers of Patients (Pts) with Myeloproliferative Neoplasms (MPNs) in the United States: Results from the Living with MPNs (LWMPN) Survey
Andrew Bai, MS, Ruben A. Mesa, MD, FACP, Dilan Paranagama, PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, PhD
The MPNs myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are associated with a variety of burdensome symptoms (BMC Cancer. 2016;16:167) and reduced survival compared with the general population (PLOS One. 2014;9:e90299).
Patient navigation has been shown to improve patient engagement and participation in clinical trials and reduce barriers to cancer care.
Sarah Cannon’s San Antonio market was seeking a way to effectively improve key quality and operational navigation metrics on their monthly Navigation Market Scorecard.
Work is central for most adults in the United States, including women with breast cancer.
Adverse Event Management During Treatment with Everolimus plus Exemestane for Postmenopausal Hormone Receptor+Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer (ABC)
The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.
Biomarker Testing in Metastatic Non–Small Cell Lung Cancer: Process Gaps and Best Practices Reported by Nurse Navigators and Nurse Practitioners
This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps.
Efficacy and Safety of Ribociclib for the Treatment of Advanced Breast Cancer: A Review of Subgroup Analyses from the Phase 3 Trial MONALEESA-2
Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease).
Evidence-Based Statistics on Complete Prevention and Rapid Sustained Elimination of Chemoradiation Mucositis by ProThelial
Of the 1.6 million individuals annually diagnosed with cancer, 522,166 received chemoradation, with 234,975 developing toxic mucositis and 20% dying within 5 years due largely to mucositis-mediated unplanned treatment breaks.
Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.
Patient-Reported Symptoms Reduce Health-Related Quality of Life Among Patients Undergoing Treatment for Metastatic Cancer
Symptoms that patients with cancer experience, either due to their illness or as a result of cancer treatment, are known to diminish their health-related quality of life.
Pooled Analysis of Safety with Extended 3-Year Follow-up Across Combination Dabrafenib and Trametinib (D+T) Phase 3 Trials
Significantly improved outcomes with D+T vs BRAF inhibitor (BRAFi) monotherapy have been demonstrated in phase 3 BRAF V600E/K–mutant melanoma trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]), supporting use of D+T as a treatment for this disease.
Single-Agent Ibrutinib in Patients with Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia: The 5-Year Experience
John C. Byrd, MD, Alvina D. Chu, MD, Steven Coutre, MD, Tony Lin, PharmD, Ying Luan, PhD, Fan Ny, NP, Jillian Settlemire, RN
Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy.
The Chimeric Antigen Receptor T-Cell Treatment Journey: Patient and Nursing Education for Managing the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel for the Treatment of Aggressive, Refractory Non-Hodgkin Lymphomas
Chimeric antigen receptor (CAR) T cells are engineered from a patient’s own immune cells to redirect them to attack tumor cells.
Treatment Options for Premenopausal Women with Hormone Receptor_Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (ABC)
Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.
Results 1 - 42 of 42